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HPV16 E6 interacts with and degrades tumour suppressor protein TSC2 leading to the phosphorylation of p70 S6 kinase. We
studied the association of S6 kinase phosphorylation and HPV16 infection in cervical cancer and esophageal cancer.
Immunohistochemistry was used to assess phosphorylated S6 kinase (Thr 389) and phosphorylated S6 (Ser235/236) in 140
cervical cancer and 161 esophageal cancer specimens. Immunohistochemical staining for pS6 kinase and pS6 was significantly more
frequent in the HPV16-infected cervical cancer specimens than the HPV16-negative specimens. In contrast, the expression of S6
kinase was similar in both HPV16-positive and -negative samples. The phosphorylation of Akt, the key regulator of S6 kinase, was also
detected. Our analysis showed that Akt phosphorylation was unaffected by HPV16 infection. These results together with our
previous study suggest that HPV16 modifies S6 kinase activation via mechanism, which activates S6 kinase downstream of Akt
function.
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Human papillomavirus (HPV) is a causal agent of cervical cancer
and a risk factor for the other epithelial cancer development
including esophageal squamous cell carcinomas (zur Hausen,
1999; Bosch et al, 2002; Kari Syrjanen, 2006). Two viral proteins,
E6 and E7, are expressed in nearly all cervical cancers and are both
necessary and sufficient for immortalisation of primary human
keratinocytes in vitro (Hawley-Nelson et al, 1989; Munger et al,
1989; Hudson et al, 1990). The inactivation of tumour suppressor
proteins, p53 and Rb by E6 and E7, respectively, plays the major
role in HPV-induced tumourigenesis (Dyson et al, 1989; Munger
et al, 1989; Scheffner et al, 1990; Werness et al, 1990; Heck et al,
1992). In addition, a growing number of proteins involved in the
broad spectrum of cellular functions have been found to be
interfered by E6 or E7. We have previously identified tumour
suppressor protein TSC2 as the novel target of HPV16 E6. HPV16
E6 interacts with TSC2 and causes the proteasome-mediated
degradation of TSC2 resulting in the phosphorylation of S6 kinase
even in the absence of insulin (Lu et al, 2004).
Recent studies have revealed that TSC2 plays an important role
in the cell growth and proliferation pathway, in which TSC2 forms
a functional complex with TSC1 and negatively regulates both
growth factor and nutrient-dependent activation of mTOR
signalling to its downstream targets S6 kinase and 4EBP1 (Gao
et al, 2002; Manning and Cantley, 2003; Saucedo et al, 2003;
Stocker et al, 2003; Hay and Sonenberg, 2004). The negative
regulatory role of the complex is achieved by TSC2 GTPase-
activating protein activity towards Rheb. Abrogation of TSC2
function by HPV16 E6 may therefore contribute to HPV16-induced
proliferation and tumourigenesis.
In this study, we evaluate the phosphorylation of S6 kinase using
immunochemical staining in cervical cancer and esophageal
cancer tissues and have correlated pS6K staining with HPV16
infection in the patients studied.
MATERIALS AND METHODS
Patient selection
One hundred and forty cervical cancers diagnosed between 2000
and 2004, and 161 esophageal cancers diagnosed in 2004 were
identified from Anyang Cancer Hospital, China. Tumour material
consisted of formalinfixed, paraffin-embedded tumour blocks.
Tumours were histologically typed and graded.
Detection of HPV16 infection
DNA was extracted from the paraffin sections as described (Nindl
et al, 2004). For HPV16 DNA detection, E7 was amplified with the
forward primer 50-GATGAAATAGATGGTCCAGC-30 and the
reverse primer 50-GCTTTGTACGCACAACCGAAGC-30 as de-
scribed (Walboomers et al, 1999). In PCR reaction, b-actin PCR
analysis was used to validate the DNA quality. Mouse liver tissue
was used in the sample process and PCR analysis to monitor the
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scontamination. PCR mixtures contained 10mM Tris–HCl (pH 8.3),
50mM KCl, 3.5mM MgCl2, 0.01% gelatin, 200pmol each primer,
4U Taq DNA polymerase (Promega, Madison, WI, USA) and
100ng DNA. The cycling conditions were 941C for 40s, 571C for
40s and 721C for 40s for 40 cycles.
Immunohistochemistry
Sections were deparaffinised in xylene, washed in graded ethanol
and followed in phosphate-buffered saline (PBS). The endogenous
peroxidase activity was blocked with PBS containing 3% hydrogen
dioxide. Samples were then pretreated with target retrieval citrate
buffer in a microwave for 15min and washed three times with PBS.
The nonspecific binding was blocked by incubation in PBS
containing 10% goat serum for 1h. Slides were stained with IHC-
specific phosphorylated Thr 389 S6K antibody (1:500 dilution,
Cell Signalling Technologies Inc., Beverly, MA, USA), S6K antibody
(1:500 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
phosphorylated Ser 235/236 S6 antibody (1:100 dilution, Cell
Signalling Technologies Inc.) and phosphorylated Ser 473 Akt
antibody (1:200 dilution, Cell Signalling Technologies Inc.) at 41C
overnight. The biotinylated secondary antibody and HRP-labelled
streptavidin were then added and incubated at 371C for 30min.
The signal was developed in DAB–H2O2 solution. The slides were
counterstained with hemotaxylin, and then examined by light
microscopy. The representative slides stained by different
antibodies are shown in Figure 1. The staining was scored on a
scale from 0 to IV as follows: 0, less than 5% cells were stained; I,
5–25% cells were stained; II, 25–50% cells were stained; III, 50–
75% cells were stained; and IV, more than 75% cells were stained.
Scores I–IV were classified as positive, while score 0 was negative.
pS6K pS6 S6K pAkt 
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Figure 1 Immunohistochemistry staining of pS6K, pS6, S6K and pAKT in cervical cancer and esophageal cancer tissues. (A) Positive control of pS6K, pS6,
S6K and pAKT in breast cancer (pS6K, pS6, S6K) and prostate cancer (pAKT) tissues. (B) Positive staining of pS6K, pS6, S6K and pAKT in cervical cancer
tissues. (C) Negative staining of pS6K, pS6, S6K and pAKT in cervical cancer tissues. (D) Positive staining of pS6K, pS6, S6K and pAKT in esophageal cancer
tissues. (E) Negative staining of pS6K, pS6, S6K and pAKT in esophageal cancer tissues.
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sStatistical analysis
The w
2-test was used to investigate the independence of categorical
variables. The P-value reported was two sided, and values of
Po0.05 were considered significant. Statistical analysis was
performed and statistical calculations were carried out using
SAS 8.0.
RESULTS
Patient characteristics are listed in Table 1. Since we have found
that TSC2 specifically binds to HPV16 E6 and leads to the elevated
S6 kinase phosphorylation independent of extra cellular stimuli, to
examine if upregulation of active S6 kinase occurs in vivo as a
result of HPV16 infection, we determined phosphorylated S6
kinase in cervical cancer and esophageal cancer with or without
HPV16 infection. The presence of HPV16 was detected by
amplification of HPV16 E7 gene fragment. Among 140 cervical
cancer specimens, 102 were HPV16 positive (72.9%). In case of
esophageal cancer, 97 out of 160 (60.2%) were HPV16 positive.
The phosphorylation of p70 S6 kinase was detected using
immunohistochemical stain with antibody specifically against
phosphorylated S6 kinase (Thr 389). The degree of immune
staining was scored as described in Materials and Methods. In
cervical cancer, 43 (42.2%) HPV16-positive specimens were scored
pS6K staining positive I and above, while 3 (7.9%) HPV16-negative
specimens were stained with the same degree (P¼0.000). Thirty
(29.4%) HPV16 positives and 1 (2.6%) HPV16 negatives were
stained as degree II and above (Po0.002) (Table 2).
In order to confirm the effect of HPV16 on the activation of S6
kinase, we detected the phosphorylation of S6 using anti-phospho-
S6 antibody (Ser235/236). Seventy-one (69.6%) of HPV16-positive
specimens were scored degree I and above, and 51 (50%) of HPV16
positives were degree II and above. In contrast, 12 (31.6%) of
HPV16 and 9 (23.7%) of HPV16 negatives were found in the
corresponding groups (P¼0.000 and Po0.009, respectively).
In esophageal cancer, 26 (26.8%) HPV16-positive specimens
were pS6K positive with degree I and above staining, while 5
(7.8%) of HPV16 negatives were pS6K positive with corresponding
degree (Po0.005). No significant difference was found between
HPV16 positives and negatives with degree II and above pS6K-
positive staining. No significance of pS6 staining at any degree was
found between HPV16 positives and negatives (Table 3).
In order to exclude the possibility that elevated S6 kinase,
phosphorylation was caused by the consequence of increased S6
kinase expression, the specimens were stained with anti-S6 kinase
antibody. A 78.4% of HPV16-positive and 78.9% of HV16-negative
cervical cancers were S6K positive with degree I and above
(P¼1.000). In esophageal cancers, 61.9% of HPV16 positives and
56.3% of HPV16 negatives were S6K positive with degree I and
above (P¼0.586).
The serine/threonine kinase Akt plays a central role upstream
mTOR and S6 kinase in PI3Kinase pathway. The activity of AKT is
upregulated in many human cancers leading to S6 kinase
Table 1 Patient characteristics
Cervical cancer
(N¼140)
ESCC
(N¼161)
Age (year)
Median (range) 48 (21–80) 58 (36–77)
Cell type (%)
Squamous cell 140 (100) 161 (100)
HPV status (%)
HPV 16+ 102 (72.9) 97 (60.2)
HPV 16  38 (27.1) 64 (39.8)
Histologic grade
High-differentiated tumour 7 11
Mild-differentiated tumour 71 102
Low-differentiated tumour 47 48
Undefined cancer 15 0
Table 2 Immunohistochemical analysis for p-S6K, p-S6, S6K and p-AKT in cervical cancer tissues
IHC score
Group Total number IV III II I 0 XI( % ) P XII (%) P
p-S6K HPV16+ 102 10 5 15 13 59 43 (42.2) 30 (29.4)
HPV16  38 1 0 0 2 35 3 (7.9) 0.000 1 (2.6) 0.002
p-S6 HPV16+ 102 18 13 20 20 31 71 (69.6) 51 (50.0)
HPV16  38 4 3 2 3 26 12 (31.6) 0.000 9 (23.7) 0.009
S6K HPV16+ 102 41 11 12 16 22 80 (78.4) 64 (62.7)
HPV16  38 12 8 4 6 8 30 (78.9) 1.000 24 (63.2) 1.000
p-Akt HPV16+ 102 2 1 3 4 92 10 (9.8) 6 (5.9)
HPV16  38 0 0 3 2 33 5 (13.2) 0.792 3 (7.9) 0.965
Table 3 Immunohistochemical analysis for p-S6K, p-S6, S6K and p-AKT in ESCC tissues
IHC score
Group Total number IV III II I 0 X1 (%) P X2( % ) P
p-S6K HPV16+ 97 6 5 4 11 71 26 (26.8) 15 (15.5)
HPV16  64 1 1 2 1 59 5 (7.8) 0.005 4 (16.3) 0.128
p-S6 HPV16+ 97 2 1 5 15 74 23 (23.7) 8 (8.2)
HPV16  64 0 0 2 7 55 9 (14.1) 0.194 2 (3.1) 0.325
S6K HPV16+ 97 9 12 15 24 37 60 (61.9) 36 (37.1)
HPV16  64 6 10 7 13 28 36 (56.3) 0.586 23 (35.9) 1.000
p-Akt HPV16+ 97 0 0 0 6 91 6 (6.2) 0
HPV16  64 0 0 0 3 61 3 (4.7) 0.957 0 1.000
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next tested the phosphorylation of Akt in HPV16-infected cancer
specimens. An antibody specifically against phosphorylated Akt
(Ser 473) was used for immunohistochemical stain. In cervical
cancer group, 9.8% HPV16 positives and 13.2% HPV negatives
were pAkt positive with degree I and above (P¼0.792). In
esophageal cancer group, 6.2% HPV16 positives and 4.7% HPV16
negatives were pAkt positive with degree I and above (P¼0.957).
The representative examples of pS6K, pS6, S6K and pAkt
staining are shown in Figure 1. The brownish signals represent the
positive staining. The phosphorylated S6K and S6 were found
mainly in the cytoplasm, while S6K was in both cytoplasm and
nucleus. The phosphorylated Akt was mainly in the cytoplasm. The
positive controls used were a breast cancer specimen for S6K, pS6
and pS6K, and a prostate cancer specimen for pAkt.
DISCUSSION
Human papillomaviruses play an etiological role in the develop-
ment of cervical cancer and several other cancers. Oncogenic HPV
E6 and E7 interrupt the host cellular function and therefore take
the principal contribution for HPV-induced tumourigenesis. We
have previously reported that HPV16 E6 binds to tumour
suppressor protein TSC2 and inferences with its suppressor
function in insulin-induced cell growth and proliferation-signal-
ling pathway leading to activate S6 kinase downstream of Akt
activation (Lu et al, 2004). In the present study we demonstrate
that S6 kinase phosphorylation was significantly increased in
HPV16-infected cervical cancer. In parallel, the phosphorylation of
S6 augmented. In HPV16-infected esophageal cancer specimens,
the alteration of S6 kinase phosphorylation was not as significant
as in cervical cancer specimens. In particular, there was no
difference of S6 phosphorylation between HPV16-positive and -
negative specimens. The discrepancy between cervical cancer and
esophageal cancer might be resulted from much lower detectable
level of pS6 kinase and pS6 detected in esophageal cancer
specimens. Alternatively, the expression of HPV16 E6 may differ
in those two group specimens and subsequently affect the
activation of S6 kinase differently. We also showed that increased
phosphorylation of S6 kinase was resulted from neither elevated S6
kinase expression nor Akt activation in specimens with HPV16
infection.
TSC2 is a key negative regulator of mTOR signalling pathway, in
which TSC2 acts as a GTPase-activating protein towards Rheb,
thereby inhibiting mTOR. Phosphorylation of TSC2 influences its
activity within the complex with TSC1. At least three kinases, Akt,
RSK1 and MAPK, are involved in TSC2 phosphorylation (Jozwiak,
2006). Several studies reported that HPV proteins target the
components of PI3 kinase and Akt-mediated cell growth pathway.
For instance, HPV E6 proteins interact with the membrane-
associated guanylate kinase homologues (MAGUKs) MAGI-2 and
MAGI-3 for degradation (Thomas et al, 2002). MAGI-2 and MAGI-
3 have been reported to be associated with PTEN (Wu et al, 2000),
the other negative regulator of the insulin-induced growth
pathway, and enhance the ability of PTEN to suppress Akt
activation. The degradation of MAGI-2 and MAGI-3 by E6 may,
therefore, result in the abolishment of PTEN function resulting in
the activation of Akt-mediated cell growth. In addition, HPV-16 E7
upregulates AKT activity in both Rb-dependent and -independent
manner (Westbrook et al, 2002; Pim et al, 2005; Menges et al,
2006). Taken together, these results highlight the importance of
interference with the PI3 kinase/Akt-mediated signalling pathway
in HPV-induced tumourigenesis. In the current study, we did not
observe enhanced Akt phosphorylation in HPV16-positive speci-
mens. This might be caused by that immunohistochemistry is not
sensitive enough to detect Akt activation in HPV-infected samples.
However, it is also possible that HPV proteins direct target
components of this pathway downstream of Akt, or even
independent of this pathway in certain condition. Therefore, the
activation of Akt might remain unchanged. For instance, our
previous study showed that expression of HPV16 E6 promoted the
degradation of TSC2 and phosphorylation of S6 kinase and S6 in
the absence of insulin stimulation, while phosphorlation of Akt
was unchanged in the presence and absence of HPV16 E6 (Lu et al,
2004). The results presented here support our previous study.
In addition, HPV proteins also activate MAPK pathway. HPV16
E6 increases the phosphorylation of MAPK and MER (Chakrabarti
et al, 2004). HPV16 E5 promotes the activation of EGFR and thus
enhances the RAS/RAF/MAPK signalling cascade (Kim et al, 2006).
Further investigation on why and how HPV oncoproteins
preferentially target the different components in this pathway will
be of great help for understanding HPV-induced tumourigenesis.
Recent studies also found that amplification of the PIK3CA gene
accompanied by serine 473 phosphorylation of AKT is common in
cervical cancers and it seems to be an independent event to HPV
infection (Ma et al, 2000; Zhang et al, 2002; Bertelsen et al, 2006).
Under our current condition, only 9.8% of cervical cancers and
6.2% of esophageal cancers were pAkt positive. This discrepancy is
unlikely due to a technical issue since we have repeated the
detection using antibodies from different batches and a positive
control from the manufacture was always used to monitor the
sensitivity. One possible explanation is that PIK3CA gene
amplification is corresponding to the progression of disease. In
our analysis, tumours were not classified by stages. In addition,
Kim et al (2006) reported that Akt phosphorylation contributes to
radioresistance in cervical cancer. A more detailed analysis is
required to define the Akt phosphorylation-related disease stage
and progression.
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